Glenfarne Merger Corp. is a blank check company newly incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. We have not selected any business combination target and we […]

We are a recently formed blank check company incorporated as a Cayman Islands exempted company on October 7, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have […]

We intend to focus on acquisition targets with a presence in Europe, the Middle East and Africa, with high potential for EMEA entrance or those who would benefit from being deployed in EMEA to then expand to different regions. We will concentrate our efforts on companies that play a key role in the future of […]

We intend to focus our search for targets in the Israeli technology industry, including those engaged in cybersecurity, automotive technology, fintech, enterprise software, cloud computing, semiconductors, medical technology, artificial intelligence (“AI”) and robotics and that offer a differentiated technology platform and products. (Incorporated in the Cayman Islands)

AF Acquisition Corp. is a newly incorporated blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination […]

Our purpose is to enable and accelerate the field of proteomics by providing a platform of products and services, developed with key opinion leaders (KOLs), that are deployed across major biopharmaceutical companies and leading clinical and academic institutions, to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. […]

We are a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Our approach activates Vg9Vd2 T cells, a specific and relatively abundant gamma-delta effector T cell subset, upon cross-linking to a selected tumor target by our bispecific […]

Alignment is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors. We deliver this experience through our Medicare Advantage plans, which are customized to meet the needs of individual seniors across the United States.  We created Alignment based on the frustrating experiences we had when our parents and other loved ones needed […]

(Note: This is a blank-check company or SPAC IPO of common stock – and NOT units. Most SPAC IPOs are unit offerings.) We intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare industry, […]

We intend to focus our search on companies with favorable growth prospects and attractive returns on invested capital. Jay R. Bloom and Dean C. Kehler, our co-chairmen and co-CEOs, are managing partners of Trimaran Capital Partners, which they co-founded in 1998.